Core Insights - SciSparc Ltd. has announced a collaboration with Clearmind Medicine Inc. leading to the filing of a new international patent application for a treatment targeting anorexia, bulimia, and other eating disorders [1][2] Company Overview - SciSparc Ltd. is a specialty clinical-stage pharmaceutical company focused on developing therapies for central nervous system disorders, with a portfolio that includes cannabinoid pharmaceuticals [4] - The company is engaged in drug development programs targeting conditions such as Tourette Syndrome, Alzheimer's disease, and autism spectrum disorder [4] Collaboration Details - The patent application involves the use of 3-Methylmethcathinone (3-MMC) in combination with SciSparc's Palmitoylethanolamide (PEA), aiming to address neurobiological and psychological factors associated with eating disorders [2] Industry Context - Eating disorders are serious mental health conditions affecting up to 70 million people globally, with a prevalence increase from 3.4% to 7.8% between 2000 and 2018 [3] - These disorders are among the top ten leading causes of disability among young women and have one of the highest mortality rates compared to other mental disorders [3] Clearmind Medicine Overview - Clearmind Medicine Inc. is a clinical-stage psychedelic pharmaceutical biotech company focused on developing psychedelic-derived therapeutics for health issues like alcohol use disorder [5] - The company holds a portfolio of nineteen patent families, including 31 granted patents, and aims to expand its intellectual property [6]

Core Viewpoint - Clearmind Medicine Inc. has filed a new international patent application for a proprietary treatment targeting anorexia, bulimia, and other eating disorders, highlighting its commitment to developing innovative therapies for under-treated mental health conditions [1][4]. Company Overview - Clearmind Medicine Inc. is a clinical-stage biotech company focused on the discovery and development of novel psychedelic-derived therapeutics aimed at addressing significant health issues, including eating disorders and alcohol use disorder [5]. - The company currently holds an intellectual property portfolio consisting of nineteen patent families, including 31 granted patents, and plans to seek additional patents as warranted [6]. Treatment Development - The new patent application covers the use of 3-Methylmethcathinone (3-MMC) in combination with Palmitoylethanolamide (PEA), targeting the neurobiological and psychological factors associated with eating disorders [2]. - The company aims to provide new treatment options for individuals struggling with eating disorders through the therapeutic potential of 3-MMC and PEA [4]. Industry Context - Eating disorders are serious mental health conditions that significantly impact health, emotions, and daily functioning, with up to 70 million people affected globally [3]. - The prevalence of eating disorders increased from 3.4% to 7.8% between 2000 and 2018, indicating a growing public health concern [3].

Core Viewpoint - Clearmind Medicine Inc. has initiated its U.S. clinical trial for its psychedelic-derived treatment CMND-100 aimed at addressing Alcohol Use Disorder (AUD), marking a significant step in the development of innovative therapies for this under-treated health issue [1][3]. Group 1: Clinical Trial Details - The clinical trial site at Yale School of Medicine's Department of Psychiatry has been activated, with patient enrollment set to begin [1]. - The trial will be led by Dr. Anahita Bassir Nia, M.D., and will also take place at Johns Hopkins University School of Medicine and the IMCA Center in Israel [2]. Group 2: Company Overview and Objectives - Clearmind is a clinical-stage biotech company focused on developing psychedelic-derived therapeutics to address significant health problems, including AUD [4]. - The company aims to research and commercialize psychedelic-based compounds as regulated medicines, foods, or supplements [4]. Group 3: Intellectual Property - Clearmind's intellectual property portfolio includes nineteen patent families and 31 granted patents, with plans to seek additional patents as necessary [5].

Core Insights - Clearmind Medicine Inc. is hosting a live webinar titled "Gazing Through the Crystal Ball" on May 21, 2025, focusing on the evolving landscape of psychedelic science and business amid changing FDA policies and political climates [1] - The company is a clinical-stage biotech firm dedicated to developing psychedelic-derived therapeutics to address significant under-treated health issues, particularly Alcohol Use Disorder (AUD) [7] Event Details - The webinar will feature a panel of experts, including Rick Doblin, PhD, a pioneer in psychedelic-assisted therapy; Robin Carhart-Harris, PhD, known for his work in psychedelic neuroscience; and Dr. Adi Zuloff-Shani, CEO of Clearmind, who is leading the development of CMND-100 for AUD [2][3][4] - The discussion will be moderated by Shannon Smadella, a recognized advocate in the psychedelic space [6] Company Overview - Clearmind's primary objective is to research and develop psychedelic-based compounds for commercialization as regulated medicines, foods, or supplements [7] - The company holds an intellectual property portfolio consisting of nineteen patent families and 31 granted patents, with plans to seek additional patents as necessary [8]

Vancouver, Canada, April 21, 2025 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (NASDAQ:CMND), (FSE: CWY0) ("Clearmind" or the "Company"), a clinical-stage biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, is pleased to announce its upcoming live webinar titled "Gazing Through the Crystal Ball." The event is scheduled for May 21, 2025, at 12:00 PM ET (9:00 AM PT) and will feature a distinguished panel of experts discuss ...

Core Insights - Clearmind Medicine Inc. has received a Notice of Allowance for a patent related to its MEAI treatment for binge behavior, enhancing its intellectual property protection and portfolio [1][2][3] Company Overview - Clearmind is a clinical-stage biotech company focused on developing psychedelic-derived therapeutics to address significant health issues, including alcohol use disorder [4] - The company aims to research and commercialize psychedelic-based compounds as regulated medicines, foods, or supplements [4] Intellectual Property - Clearmind's intellectual property portfolio includes nineteen patent families and 31 granted patents, with plans to seek additional patents as needed [5] - The recent patent allowance strengthens the company's position in the psychedelic therapeutics space and supports the development of its MEAI program [2][3]

Company Overview - Clearmind Medicine Inc. is a clinical-stage biotech company focused on developing psychedelic-derived therapeutics to address under-treated health issues, particularly Alcohol Use Disorder (AUD) [1][7] - The company has a proprietary drug candidate, CMND-100, which is based on MEAI and aims to provide a novel treatment approach for AUD by modulating reward mechanisms associated with addictive behavior [4] Clinical Trial Initiation - Clearmind has initiated its Phase I/IIa clinical trial for CMND-100 at Johns Hopkins University School of Medicine, marking a significant milestone towards FDA approval [1][3] - The trial will also take place at Yale School of Medicine and IMCA Center in Israel, indicating a strong foundation for evaluating the clinical potential of CMND-100 [2][3] Study Objectives - The clinical trial is designed to assess the safety, tolerability, and pharmacokinetics of CMND-100 in individuals diagnosed with AUD, along with preliminary efficacy evaluations to examine its potential in reducing alcohol cravings and consumption [3] Market Context - Alcohol Use Disorder is a major global health challenge, affecting approximately 400 million people aged 15 and older, with 209 million experiencing alcohol dependence [6] - The disorder contributes to 2.6 million deaths annually, accounting for 4.7% of all global deaths, highlighting the urgent need for innovative therapeutic solutions [6] Regulatory and Intellectual Property - Clearmind aims to commercialize its psychedelic-based compounds as regulated medicines, foods, or supplements, and currently holds a portfolio of nineteen patent families with 31 granted patents [7][8]

Core Insights - Clearmind Medicine Inc. has announced the publication of an international patent application in collaboration with Yissum Research Development Company, focusing on innovative psychedelic-based compounds for treating mental health disorders and addiction [1][2] Company Overview - Clearmind is a clinical-stage biotech company dedicated to discovering and developing novel psychedelic-derived therapeutics aimed at addressing significant under-treated health issues, including alcohol use disorder [3] - The company currently holds an intellectual property portfolio consisting of nineteen patent families and 31 granted patents, with plans to seek additional patents as warranted [4] Collaboration and Innovation - The collaboration with Yissum has produced highly innovative compounds that aim to surpass the limitations of traditional psychedelics, reflecting the company's commitment to advancing safe and effective solutions for mental health and addiction disorders [2] - The patent application is part of an exclusive worldwide licensing agreement with Yissum, allowing Clearmind to develop, research, manufacture, market, and commercialize products derived from a patent-pending synthesis of psychedelic compounds [2]

Core Insights - Clearmind Medicine Inc. has launched its Electronic Data Capture (EDC) system to support its Phase I/II clinical trial for a MEAI-based treatment targeting Alcohol Use Disorder (AUD) [1][2][5] - The EDC system is designed for real-time, secure data collection and monitoring across all trial sites, ensuring compliance and integrity of the study [2][3][4] Company Overview - Clearmind is a clinical-stage biotech company focused on developing psychedelic-derived therapeutics to address under-treated health issues, particularly alcohol use disorder [6] - The company holds an intellectual property portfolio consisting of nineteen patent families and 31 granted patents, with plans to seek additional patents as necessary [7] Clinical Trial Details - The clinical trial aims to evaluate the safety, tolerability, and efficacy of Clearmind's MEAI-based compound in individuals with AUD [1][2] - The EDC system includes features such as automated edit checks, real-time validation, and a secure randomization process to enhance data accuracy and compliance [3][4]

Core Insights - Clearmind Medicine Inc. has announced the arrival of its drug candidate CMND-100 in the U.S., marking a significant milestone as it prepares to initiate its FDA-approved Phase I/IIa clinical trial for Alcohol Use Disorder (AUD) [1][2][3] - CMND-100 is a proprietary MEAI-based oral drug that aims to reduce alcohol consumption and cravings through a novel mechanism of action, positioning the company to potentially disrupt the AUD treatment market [2][3] Company Overview - Clearmind is a clinical-stage biotech company focused on developing psychedelic-derived therapeutics to address major health issues, including AUD [4] - The company has a robust intellectual property portfolio consisting of 19 patent families and 31 granted patents, with plans to seek additional patents as warranted [5] Market Opportunity - The global market opportunity for AUD treatments is estimated at $35 billion, with current solutions being limited and ineffective [3] - The Phase I/IIa clinical trial will assess the safety and efficacy of CMND-100 in reducing alcohol consumption, conducted at leading research institutions including Yale and Johns Hopkins [3]